• By ICR Secretariat
  • Posted Thursday, April 7, 2022

In major shake-up, Novartis combines pharma and oncology units, leaving 3 top execs without jobs

https://www.fiercepharma.com/pharma/major-shakeup-novartis-combines-pharma-oncology-units-leaving-cancer-commercial-head-rd

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover ahead of a possible spinoff of generics unit Sandoz, pushing out three C-level executives and preparing for layoffs.